Okada Atsushi, Sugano Yasuo, Nagai Toshiyuki, Takashio Seiji, Honda Satoshi, Asaumi Yasuhide, Aiba Takeshi, Noguchi Teruo, Kusano Kengo F, Ogawa Hisao, Yasuda Satoshi, Anzai Toshihisa
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.
Circ J. 2016;80(4):913-23. doi: 10.1253/circj.CJ-15-1326. Epub 2016 Feb 26.
There are limited studies regarding the prognostic value of coagulation abnormalities in heart failure patients. The clinical significance of prothrombin time international normalized ratio (INR), a widely accepted marker assessing coagulation abnormalities, in acute decompensated heart failure (ADHF) remains unclear.
Among 561 consecutive patients admitted for ADHF, INR was assessed in 294 patients without prior anticoagulation therapy, acute coronary syndrome, liver disease, or overt disseminated intravascular coagulation. Increased INR on admission was positively associated with increased levels of thrombin-antithrombin complex, C-reactive protein, total bilirubin, γ-glutamyl transpeptidase, inferior vena cava diameter, tricuspid regurgitation severity, markers of neurohormonal activation, and also negatively associated with decreased albumin, cholinesterase, and total cholesterol. In contrast, there was no significant association with left ventricular ejection fraction, serum sodium or blood urea nitrogen. Multivariate analysis showed that increased INR was independently associated with increased all-cause mortality (hazard ratio 1.89 per 0.1 increase, 95% confidence interval 1.14-3.13, P=0.013) during the median follow up of 284 days. Increased INR also had a higher prognostic value compared to risk score models including the Model for End-Stage Liver Disease (MELD) score or the MELD excluding INR (MELD-XI) score.
Increased INR is an independent predictor of all-cause mortality in ADHF patients without anticoagulation, reflecting coagulation abnormalities and hepatic insufficiency, possibly through systemic inflammation, neurohormonal activation and venous congestion.
关于凝血异常在心力衰竭患者中的预后价值的研究有限。凝血酶原时间国际标准化比值(INR)作为评估凝血异常的一个广泛接受的指标,在急性失代偿性心力衰竭(ADHF)中的临床意义仍不明确。
在561例因ADHF连续入院的患者中,对294例无既往抗凝治疗、急性冠状动脉综合征、肝病或明显弥散性血管内凝血的患者进行了INR评估。入院时INR升高与凝血酶 - 抗凝血酶复合物、C反应蛋白、总胆红素、γ-谷氨酰转肽酶、下腔静脉直径、三尖瓣反流严重程度、神经激素激活标志物水平升高呈正相关,与白蛋白、胆碱酯酶和总胆固醇降低呈负相关。相比之下,与左心室射血分数、血清钠或血尿素氮无显著相关性。多变量分析显示,在284天的中位随访期间,INR升高与全因死亡率增加独立相关(每增加0.1,风险比为1.89,95%置信区间为1.14 - 3.13,P = 0.013)。与包括终末期肝病模型(MELD)评分或排除INR的MELD(MELD-XI)评分在内的风险评分模型相比,INR升高也具有更高的预后价值。
INR升高是未接受抗凝治疗的ADHF患者全因死亡率的独立预测因子,反映了凝血异常和肝功能不全,可能是通过全身炎症、神经激素激活和静脉淤血导致的。